- Previous Close
3.3700 - Open
3.4000 - Bid 3.3200 x 100
- Ask 3.3900 x 100
- Day's Range
3.3000 - 3.4000 - 52 Week Range
2.8800 - 6.2500 - Volume
42,085 - Avg. Volume
87,107 - Market Cap (intraday)
57.493M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-9.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.33
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
www.muraloncology.comRecent News: MURA
View More
Performance Overview: MURA
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MURA
View MoreValuation Measures
Market Cap
57.49M
Enterprise Value
-108.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.33
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-81.05%
Return on Equity (ttm)
-178.34%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-173.3M
Diluted EPS (ttm)
-9.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
204.7M
Total Debt/Equity (mrq)
5.42%
Levered Free Cash Flow (ttm)
-92.15M
Research Analysis: MURA
View MoreCompany Insights: MURA
MURA does not have Company Insights